Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00897247 · ClinicalTrials.gov registry record
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
A clinical trial, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- 494
- Enrollment target
NCT00897247 is a clinical trial that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 494 participants.
The verdict
NCT00897247 has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- 494 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite.
Interventions
- GENETIC microarray analysis
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- GENETIC proteomic profiling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00897247
The ClinicalTrials.gov registry entry for NCT00897247 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which microarray analysis is the first listed.
NCT00897247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00897247 about?
NCT00897247 is a clinical study titled "Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite". RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking for biomarkers to...
What is the current status of trial NCT00897247?
This trial is currently completed. The enrollment target is 494 participants. The study started on 2007-01. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00897247?
The interventions under investigation include: microarray analysis (GENETIC), protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), proteomic profiling (GENETIC).
Who is sponsoring clinical trial NCT00897247?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.